CIK 0001841387 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Candel Therapeutics, Inc.
Sign in to watch- Ticker
- CADL
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 522214851
- Phone
- 617-916-5445
- Business address
- 117 KENDRICK STREET, SUITE 450, NEEDHAM, MA, 02494
- 8-K Event Regulation FD disclosure
- 424B5 Offering Prospectus
- 8-K Event Regulation FD disclosure · Other events
- 3 Insider Initial Statement of Ownership
- 8-K Event Executive or director change
- 8-K Event Other events
- 8-K Event Executive or director change
- 8-K Event Regulation FD disclosure
- 4 Shares withheld for taxes Chief Technology Officer gave up 17,328 shares (to pay taxes)
- 4 Shares withheld for taxes Chief Executive Officer gave up 43,443 shares (to pay taxes)
- 4 Shares withheld for taxes Chief Medical Officer gave up 12,175 shares (to pay taxes)
- 4 Shares withheld for taxes Chief Scientific Officer gave up 19,748 shares (to pay taxes)
- 4 Shares withheld for taxes Chief Financial Officer gave up 20,153 shares (to pay taxes)
- 4 Grant or award Chief Executive Officer acquired 180,108 shares (grant or award)
- 4 Grant or award Chief Technology Officer acquired 104,516 shares (grant or award)
- 4 Grant or award Chief Medical Officer acquired 88,822 shares (grant or award)
- 4 Grant or award Chief Scientific Officer acquired 112,790 shares (grant or award)
- 4 Grant or award Chief Financial Officer acquired 125,717 shares (grant or award)
- 8-K Event Exit or restructuring costs
- 8-K Event Delisting notice
Page 13 of 22 · 422 filings